

(Rs. in Crores)

Sr. No.	Particulars	Year ended 31 <sup>st</sup> Mar. 2009 (Audited)	Year ended 31 <sup>st</sup> Mar. 2008 (Audited)	Consolidated year ended 31 <sup>st</sup> Mar. 2009 (Audited)	Consolidated period ended 31 <sup>st</sup> Mar. 2008 (Audited)
1. a.	Net Sales/Income from Operations	471.33	406.35	856.02	650.68
b.	Other Operating Income	4.98	15.77	7.71	19.18
2.	Expenditure				
a.	(Increase)/ Decrease in Stock in Trade and Work in Progress	(6.55)	(8.06)	(10.31)	(6.41)
b.	Consumption of Raw Materials	296.43	247.57	484.69	361.50
c.	Purchase of traded goods	---	---	---	---
d.	Employee Cost	20.07	15.64	86.33	60.55
e.	Depreciation	18.78	15.71	37.84	24.15
f.	Other Expenditure	35.52	38.29	108.81	91.52
g.	Total	364.25	309.15	707.36	531.31
3.	Profit from Operations before Other Income, Interest and Exceptional Items (1-2)	112.06	112.97	156.37	138.55
4.	Other Income	---	---	---	---
5.	Profit before Interest and Exceptional Items (3+4)	112.06	112.97	156.37	138.55
6.	Interest	19.74	11.44	39.25	14.27
7.	Profit after Interest but before Exceptional Items ( 5-6)	92.32	101.53	117.12	124.28
8.	Exceptional Items	---	---	---	---
9.	Profit from Ordinary Activities before Tax (7 + 8)	92.32	101.53	117.12	124.28
10.	Tax Expense	31.62	39.84	34.18	42.73
11.	Net Profit from Ordinary Activities after Tax (9 - 10)	60.70	61.69	82.94	81.55
12.	Extraordinary Items	---	---	---	---
13.	Net Profit for the year (11 - 12)	60.70	61.69	82.94	81.55
14.	Paid-up Equity Share Capital (face value Rs.10/- each)	17.21	16.45		
15.	Reserves excluding Revaluation Reserves as per Balance Sheet of previous accounting year	410.55	346.79	478.77	372.39
16.	Earnings Per Share (EPS) (Rs.) after Extraordinary items for the year and for the previous year				
- Basic					
- Diluted		35.27	37.49		
		30.83	32.14		
17.	Public Shareholding				
-	No. of Shares	9,176,791	9,176,791		
-	Percentage of Shareholding	53.33%	55.78%		

Notes:

- The Board of Directors have recommended a dividend of Rs.2.50 per share for the year ended March 31, 2009 subject to the approval of the members.
- The Company's main business segment is pharma packaging research solutions.
- The Company had not received any investor complaint during the period and there is no investor complaint pending for redressal at the commencement and at the end of the period.
- The consolidated results include operation of its subsidiaries viz, i) Bilcare Singapore Pte. Ltd., Singapore; ii) Bilcare GmbH, Germany; iii) Bilcare Inc, USA; iv) Bilcare Farmaceutica Embalagem E Pesquisa Ltda., Brazil; v) Bilcare (UK) Ltd., UK; vi) Bilcare GCS (Europe) Ltd., UK; vii) Bilcare SA, Switzerland; viii) Bilcare Technologies Singapore Pte. Ltd. (Formerly Singular ID Pte. Ltd.), Singapore; and ix) Bilcare Technologies Italia Srl. (Formerly Singular ID Italia Srl), Italy and 50% of the Joint Venture i.e. International Labs LLC, US. The previous year's figures of the subsidiary companies were for 15 months and hence not comparable with the current year's figures.
- The Company's request for delisting of its Equity Shares from Ahmedabad Stock Exchange Ltd. and Pune Stock Exchange Ltd. has been approved. Equity Shares will continue to remain listed on Bombay Stock Exchange Ltd (BSE).
- The previous year's figures have been regrouped / readjusted wherever necessary.
- The above Audited Financial Results were approved by the Board of Directors of the Company at its meeting held on 30th June, 2009.

**For Bilcare Limited**

Pune: 30<sup>th</sup> June, 2009

**Mohan H. Bhandari**  
Managing Director